At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 9 enrolled
Drug / intervention
PassPort(R) Transdermal Insulin Delivery Systemother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pharmacokinetic/Pharmacodynamic Study of the PassPort(R) Transdermal Insulin Delivery System in Type 1 Diabetes Patients
In Brief
A Phase 2 clinical trial evaluating PassPort(R) Transdermal Insulin Delivery System for Type 1 Diabetes. Completed, enrolled 9 participants across 1 site.
Detailed Summary
This study is designed to evaluate the pharmacokinetics/pharmacodynamics of an investigational basal insulin patch in type 1 diabetes patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2007
First PostedAug 2007
Primary CompletionNov 2007
Study CompletionDec 2007
TodayJul 2026
First PostedAug 22, 2007
Enrollment StartAug 1, 2007
Primary CompletionNov 1, 2007
Study CompletionDec 1, 2007
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 18.9 years ago
Interventions
PassPort(R) Transdermal Insulin Delivery Systemother
The PassPort(R) Transdermal Insulin Delivery System is a drug-device combination product used to create micropores in the skin to enable transdermal delivery of insulin.